Skip to main content
. 2008 Feb 7;111(8):4014–4021. doi: 10.1182/blood-2007-08-106021

Figure 1.

Figure 1

Cumulative incidence of second neoplasms among 1074 5-year survivors of pediatric non-Hodgkin lymphoma, Childhood Cancer Survivor Study, North America. The dashed line represents cumulative incidence of all malignant diagnoses, including bladder transitional cell carcinoma in situ, whereas the solid line includes diagnoses listed above in addition to 4 meningiomas (ICD-O-2: 9532.0, 953.0), 21 skin cancers (ICD-O-2: 8090.3, 8094.3), and one myelodysplastic syndrome (ICD-O-2: 9989.1). Only the first of any of these neoplasms is counted for each subject. Subjects were those alive 5 years after NHL diagnosis, excluding 6 who experienced secondary neoplasms within the first 5 years of NHL and 2 with unknown date of death.